
GARDASIL®9 FOR ADULTS
DISCUSS GARDASIL 9
WITH ADULT PATIENTS
THROUGH AGE 45.
You may be able to help protect them
from certain HPV-related cancers.

Millions of men and women
aged 27–45 may still benefit
from HPV vaccination1
Help protect your appropriate adult patients with GARDASIL 9 from certain HPV-related cancers and diseases caused by HPV Types to which they have not been exposed.
GARDASIL 9 helps protect against certain cancers caused by 7 HPV Typesa
- Cervical
- Vulvar
- Oropharyngeal*
*Continued approval contingent
upon confirmatory trial.
- Vaginal
- Anal
*Continued approval contingent
upon confirmatory trial.
aHPV Types 16, 18, 31, 33, 45, 52, and 58.
HPV is not the only cause of these cancers.
Did you know?
HPV vaccination rates are low among adults aged 27–453
The percentage of adults aged 27–45 who reported receiving ≥1 dose of an HPV vaccine
according to 2017 NHIS3:
~4%
of men
n=116/3,272
~16%
of women
n=613/3,950
Seize the opportunity to vaccinate appropriate adults aged 27–45 with GARDASIL 9.
It’s a conversation worth having
Even if your patients aged 27–45 have been exposed to one HPV type, they may still benefit from GARDASIL 9 to help protect against certain HPV-related cancers caused by HPV Types to which they haven’t been exposed.
Commercial insurance coverage for adults aged 27–45
Over 99% of commercially insured 27- to 45-year-olds are covered for GARDASIL 95,c
The information reflected here is subject to change at any time.
Additionally, this information is not inclusive of all plans that have made a decision regarding coverage for GARDASIL 9. You should contact your patient’s health plan directly for information on coverage and out-of-pocket costs to ensure that you have the most timely and accurate information.
The information provided does not guarantee that a plan’s decision on coverage will result in your out-of-pocket costs being covered.
Coverage for GARDASIL 9 is dependent on the terms and conditions of your patient’s insurance benefit, including any applicable deductible or cap. Additionally, there may be a co-pay or coinsurance that applies. A pharmacist and their staff may try an alternate benefit pathway if the claim is denied, as your patient’s coverage may be unique. A health plan’s decision to cover GARDASIL 9 does not guarantee that implementation at the regional/local level has occurred or will necessarily occur.
Please note that some plans have asked not to be included in this type of resource.
cData above from Decision Resources Group reflecting data as of January 2022 covered under the commercial medical benefit.
For your appropriate adult patients, recommend GARDASIL 9 to help prevent certain HPV-related cancers

Share with your appropriate patients:
- For most people, HPV clears on its own. But, for those who don’t clear the virus, it could cause certain cancers and diseases6,7,8
- Explain the link between HPV and certain related cancers for men and women
- Discuss GARDASIL 9 efficacy and safety profile
- GARDASIL 9 only helps to prevent diseases caused by the HPV Types covered by the vaccine to which your patient may not have been exposed
Vaccinate appropriate adults aged 27–45 with GARDASIL 9 or refer (e-prescribe) your patients to an administering pharmacy.
Reference
Reference
Reference
Reference
Reference
Reference
Reference
Reference
Reference
Reference
Reference
Reference
Reference
Reference
Reference
Reference
Annual incidence of cancer cases per year attributed to the 7 HPV Types covered by GARDASIL 92
Study Design of 2017 National Health Interview Survey (NHIS)
Indication for GARDASIL® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.
GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.
The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
GARDASIL 9 does not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a health care provider.
GARDASIL 9 has not been demonstrated to provide protection against diseases caused by:
- HPV types not covered by the vaccine
- HPV types to which a person has previously been exposed through sexual activity
Not all vulvar, vaginal, anal, oropharyngeal and other head and neck cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58.
GARDASIL 9 is not a treatment for external genital lesions; cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers; or cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), or anal intraepithelial neoplasia (AIN).
Vaccination with GARDASIL 9 may not result in protection in all vaccine recipients.
GARDASIL 9 is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL 9 or GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant].
GARDASIL ®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL 9 or GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant].
Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following HPV vaccination. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion.
Safety and effectiveness of GARDASIL 9 have not been established in pregnant women.
The most common (≥10%) local and systemic adverse reactions in females were injection-site pain, swelling, erythema, and headache. The most common (≥10%) local and systemic reactions in males were injection-site pain, swelling, and erythema.
The duration of immunity of GARDASIL 9 has not been established.
Dosage and Administration for GARDASIL 9
GARDASIL 9 should be administered intramuscularly in the deltoid or anterolateral area of the thigh.
- For individuals 9 through 14 years of age, GARDASIL 9 can be administered using a 2-dose or 3-dose schedule. For the 2-dose schedule, the second dose should be administered 6–12 months after the first dose. If the second dose is administered less than 5 months after the first dose, a third dose should be given at least 4 months after the second dose. For the 3-dose schedule, GARDASIL 9 should be administered at 0, 2 months, and 6 months.
- For individuals 15 through 45 years of age, GARDASIL 9 is administered using a 3-dose schedule at 0, 2 months, and 6 months.
Before administering GARDASIL 9, please read the Prescribing Information. The Patient Information also is available.